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Introduction
Flora in ICUs has changed with the development of new
therapies and the implementation of protocols regarding
bacterial infections. As a result, this could increase our
concerns about fungal infections and modify the indica-
tions and the way we use them.
Objectives
To assess the indications for the use of antifungal drugs
(AD) during the 2013-2014 period using data from the
ENVIN-HELICS registry.
Methods
Data regarding the use of AD in patients admitted to ICU
for over 24 hours is gathered. Different kinds of amphoter-
icin are grouped (deoxycholate, liposomal and lipid)
(AMP), as well as echinocandins (caspofungin, micafungin
and anidulafungin) (ECH). Fluconazole (FLU) and vorico-
nazole (VOR) are considered as different groups. Data
from the 3 months of each year when the registry is com-
plete is used. The indications are divided in prophylaxis,
treatment of community-acquired infections, treatment of
in-hospital acquired infection (out of ICU) and in-ICU
acquired infection treatment. Whether the AD is started
as a specific therapy or empirically is also studied; in the
latter the microbiological results (positive or negative), the
adequacy, modifications of AD, AD combination and
sequential therapies are analyzed. Results are shown as
percentages of the used AD.
Results
2417 patients were treated with AD. 400 received more
than one AD and 72 of them more than 2. Overall in-ICU
mortality was 36.4%. Length of stay average was 18.7 ( ±
19.3 ) days. First choice of AD is shown in the table.
Of 1481 cases where the AD is started empirically, the
adequacy is confirmed in 21.3%; in 45.0% of the cases
the cultures were negative or were not collected; in
15.8% the infection is not confirmed. Mortality of those
patients treated with more than one AD was 60.0%. In
62 cases (2.5%) both agents were initiated at the same
time, but only in 25 of them the combination was used
for more than 48 hours. The most frequently used com-
bination was VOR plus caspofungin (32.0%). 260
patients (10.7%) received sequential therapy; these
changes were justified as adjustment of the spectrum
(33.2%), worsening of the clinical status (31.6%), toxicity
(8.6%), development of resistance during the AD use
(0.5%) and other reasons (12.3%). Among the 59 cases
were the AD was switched due to a worsening of the
clinical status, 51 were initially treated with FLU (86.4%)
and switched to ECH in 45 cases (76.2%). Mortality in
ICU in the latter group was 59.3%.
Conclusions
AD use in critically ill patients is described. FLU was the
most frequently used AD. Microbiological confirmation
was scarce. Combined AD therapy was rarely used,
while sequential AD were more frequently administered
(10.7%). The switch to FLU was seen in order to reduce
the spectrum of the therapy, whereas ECH were the
choice when the clinical status worsened; mortality in
the latter group was high.
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Fluconazole 1296, (53.6) 48.5 63.5 48 47 61
Echinocandins 807, (33.4) 39.2 25.9 32.8 37.7 31.7
Amphotericin 89, (3.7) 3.3 3.4 5.9 3.9 2
Voriconazole 225, (9.3) 8.9 7.1 13.2 11.3 5.1
Total (n), (%) 2417,
(100.0)
1481,(61.3) 351,(14.5) 454,(18.8) 926,(38.3) 686,(28.4)
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